{"symbol":"BMY","fiscalQuarter":"Q2-2017","reportDate":"2017-07-27","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2017","postBrief":{"headline":"Bristol Myers Squibb Misses on EPS \u2014 Stock Down 3.11%","keyNumbers":[{"metric":"EPS","actual":"$0.74","expected":"N/A","surprise":"-1.36%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management highlighted ongoing challenges in the market.","They emphasized the importance of pipeline developments moving forward."],"summary":"Management expressed concerns about market conditions affecting performance. They reiterated their focus on future product launches and pipeline strength."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a 3.11% decline in stock price. Investors may be reacting to management's cautious tone regarding market challenges and the lack of updated guidance. The focus will likely shift to the company's pipeline and future product launches as key factors for recovery.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2017 earnings: EPS missed. Stock down 3.11%. Full breakdown."}}